Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London EC4N 7BL, UK
Argipressin 20 International Units /ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, sterile solution. |
20 international units argipressin (vasopressin) per ml.).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Vasopressin |
The antidiuretic action of vasopressin is ascribed to increase in reabsorption of water by the renal tubules. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract, gall bladder, urinary bladder and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. The direct effect on the contractile elements is neither antagonised by adrenergic blocking agents nor prevented by vascular denervation. |
| List of Excipients |
|---|
|
Glacial acetic acid |
Clear OPC/blue glass ampoules with white and blue rings above the OPC.
The white and blue rings are for product identification and should not be taken as break rings. The ampoules should be open cut at the OPC
Available in packs of 10 x1ml ampoules.
Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London EC4N 7BL, UK
PL 12762/0162
30th November 2004
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
